All Publications

Data provided by UCSF Profiles, powered by CTSI at UCSF
  1. Ricardo J. Antonia, Kan Toriguchi, Eveliina Karelehto, Dania Annuar, Luika Timmerman, Noura Tbeileh, Aras N. Mattis, Carlos U. Corvera, Kenzo Hirose, Eric K. Nakakura, David B. Donner, Robert S. Warren. Patient-derived organoids for personalized drug screening in intrahepatic cholangiocarcinoma. Journal of Clinical Oncology. 2020 Feb 1; 38(4_suppl):581-581. View in PubMed
  2. Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma. PLoS One. 2019; 14(7):e0219469. View in PubMed
  3. Donner DB, Ruan DT, Toriguchi K, Bergsland EK, Nakakura EK, Lin MH, Antonia RJ, Warren RS. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases. Transl Oncol. 2019 Mar; 12(3):550-560. View in PubMed
  4. Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. . 2018 12; 17(12):2702-2709. View in PubMed
  5. K. Toriguchi, M. Lin, E. Nakakura, C. Corvera, B. Hann, D. Donner, R. Warren. An approach to patient-specific treatment of intrahepatic cholangiocarcinoma (ICC): drug screens with patient-derived spheroids identify mTOR as a viable and druggable target. Hepato Pancreato Biliary. 2018 Sep 1; 20:s690-s691. View in PubMed
  6. Tartaglione G, Stoeckli SJ, de Bree R, Schilling C, Flach GB, Bakholdt V, Sorensen JA, Bilde A, von Buchwald C, Lawson G, Dequanter D, Villarreal PM, Forcelledo MF, Amezaga JA, Moreira A, Poli T, Grandi C, Vigili MG, O'Doherty M, Donner D, Bloemena E, Rahimi S, Gurney B, Haerle SK, Broglie MA, Huber GF, Krogdah AL, Sebbesen LR, Odell E, Junquera Gutierrez LM, Barbier L, Santamaria-Zuazua J, Jacome M, Nollevaux MC, Bragantini E, Lothaire P, Silini EM, Sesenna E, Dolivet G, Mastronicola R, Leroux A, Sassoon I, Sloan P, Colletti PM, Rubello D, McGurk M. Sentinel Node in Oral Cancer: The Nuclear Medicine Aspects. A Survey from the Sentinel European Node Trial. Clin Nucl Med. 2016 Jul; 41(7):534-42. View in PubMed
  7. Maines F, Caffo O, Donner D, Sperduti I, Bria E, Veccia A, Chierichetti F, Tortora G, Galligioni E. Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers. Future Oncol. 2016 Feb; 12(3):333-42. View in PubMed
  8. Schilling C, Stoeckli SJ, Haerle SK, Broglie MA, Huber GF, Sorensen JA, Bakholdt V, Krogdahl A, von Buchwald C, Bilde A, Sebbesen LR, Odell E, Gurney B, O'Doherty M, de Bree R, Bloemena E, Flach GB, Villarreal PM, Fresno Forcelledo MF, Junquera Gutiérrez LM, Amézaga JA, Barbier L, Santamaría-Zuazua J, Moreira A, Jacome M, Vigili MG, Rahimi S, Tartaglione G, Lawson G, Nollevaux MC, Grandi C, Donner D, Bragantini E, Dequanter D, Lothaire P, Poli T, Silini EM, Sesenna E, Dolivet G, Mastronicola R, Leroux A, Sassoon I, Sloan P, McGurk M. Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer. Eur J Cancer. 2015 Dec; 51(18):2777-84. View in PubMed
  9. Depeille P, Henricks LM, van de Ven RA, Lemmens E, Wang CY, Matli M, Werb Z, Haigis KM, Donner D, Warren R, Roose JP. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. Nat Cell Biol. 2015 Jun; 17(6):804-15. View in PubMed
  10. Farkas C, Martins CP, Escobar D, Hepp MI, Castro AF, Evan G, Gutiérrez JL, Warren R, Donner DB, Pincheira R. Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress. PLoS One. 2013; 8(9):e73817. View in PubMed
  11. Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013 Oct 15; 19(20):5777-87. View in PubMed
  12. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2014 Mar 20; 33(12):1590-600. View in PubMed
  13. Schiavi F, Demattè S, Cecchini ME, Taschin E, Bobisse S, Del Piano A, Donner D, Barbareschi M, Manera V, Zovato S, Erlic Z, Savvoukidis T, Barollo S, Grego F, Trabalzini F, Amistà P, Grandi C, Branz F, Marroni F, Neumann HP, Opocher G. The endemic paraganglioma syndrome type 1: origin, spread, and clinical expression. J Clin Endocrinol Metab. 2012 Apr; 97(4):E637-41. View in PubMed
  14. Gregory S. Ducker, Chloe Evelyn Atreya, Jeffrey Simko, Eric K. Nakakura, Emily K. Bergsland, David B. Donner, Kevan M. Shokat, Robert S. Warren. Effect of PIK3CA and KRAS mutations on sensitivity to ATP-competitive mTOR inhibitors in a primary xenograft model of colorectal carcinoma. Journal of Clinical Oncology. 2012 Feb 1; 30(4_suppl):483-483. View in PubMed
  15. Lin CI, Barletta JA, Nehs MA, Morris ZS, Donner DB, Whang EE, Jeong JW, Kimura S, Moore FD, Ruan DT. Thyroid-specific knockout of the tumor suppressor mitogen-inducible gene 6 activates epidermal growth factor receptor signaling pathways and suppresses nuclear factor-?B activity. Surgery. 2011 Dec; 150(6):1295-302. View in PubMed
  16. Mitra R, Guo Z, Milani M, Mesaros C, Rodriguez M, Nguyen J, Luo X, Clarke D, Lamba J, Schuetz E, Donner DB, Puli N, Falck JR, Capdevila J, Gupta K, Blair IA, Potter DA. CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET). J Biol Chem. 2011 May 20; 286(20):17543-59. View in PubMed
  17. Chi-Iou Lin, Jinyan Du, Wen Shen, Edward E. Whang, David B. Donner, Nick Griff, Frank He, Francis D. Moore, Orlo H. Clark, Daniel T. Ruan. Mitogen-Inducible Gene-6 Is a Multifunctional Adaptor Protein with Tumor Suppressor-Like Activity in Papillary Thyroid Cancer. Endocrinology. 2011 Feb 1; 25(2):373-373. View in PubMed
  18. Y. Wang, D. Donner, A. Venook, E. Bergsland, R. Warren, E. Nakakura. A Primary Xenograft Model of Pancreatic Neuroendocrine Carcinoma Maintains a Neuroendocrine Tumor Gene Expression Signature. Journal of Surgical Research. 2011 Feb 1; 165(2):296. View in PubMed
  19. Chi-Iou Lin, Jinyan Du, Wen Shen, Edward E. Whang, David B. Donner, Nick Griff, Frank He, Francis D. Moore, Orlo H. Clark, Daniel T. Ruan. Mitogen-Inducible Gene-6 Is a Multifunctional Adaptor Protein with Tumor Suppressor-Like Activity in Papillary Thyroid Cancer. Endocrine Reviews. 2011 Feb 1; 32(1):157-158. View in PubMed
  20. Lin CI, Du J, Shen WT, Whang EE, Donner DB, Griff N, He F, Moore FD, Clark OH, Ruan DT. Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer. J Clin Endocrinol Metab. 2011 Mar; 96(3):E554-65. View in PubMed
  21. Lin CI, Whang EE, Donner DB, Du J, Lorch J, He F, Jiang X, Price BD, Moore FD, Ruan DT. Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. Mol Cancer Res. 2010 Sep; 8(9):1217-26. View in PubMed
  22. Wang YC, Iezza G, Zuraek MB, Jablons DM, Theodore PR, Bergsland EK, Donner DB, Warren RS, Nakakura EK. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site. J Surg Res. 2010 Sep; 163(1):47-51. View in PubMed
  23. Eric Nakakura, Melissa Wong, Yucheng Wang, Gioia Iezza, Marlene Zuraek, Xiaochen Yuan, David Donner, Douglas Hanahan, Robert Warren, Emily Bergsland. Distinct mTOR Pathway Activity in Neuroendocrine Tumors of the Pancreas and Small Intestine Revealed by Immunohistochemical Analysis. Pancreas. 2010 Mar 1; 39(2):276. View in PubMed
  24. Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, Bergsland EK, Donner DB, Warren RS, Nakakura EK. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine. Endocr Relat Cancer. 2010 Mar; 17(1):283-91. View in PubMed
  25. E.K. Nakakura, G. Iezza, M. Zuraek, D. Jablons, P. Theodore, D. Donner, E. Bergsland, R. Warren, Y. Wang. Lack of NKX2.2 Transcription Factor Expression Distinguishes Bronchopulmonary Typical Carcinoids from Gastrointestinal Neuroendocrine Tumors. Journal of Surgical Research. 2010 Feb 1; 158(2):267. View in PubMed
  26. E.K. Nakakura, M. Zuraek, D. Donner, E. Bergsland, R. Warren, Y. Wang. Reduced GFI1 Transcription Factor Expression in Small Intestinal Neuroendocrine Tumor Metastases. Journal of Surgical Research. 2010 Feb 1; 158(2):266-267. View in PubMed
  27. Lin CI, Whang EE, Abramson MA, Jiang X, Price BD, Donner DB, Moore FD, Ruan DT. Autophagy: a new target for advanced papillary thyroid cancer therapy. Surgery. 2009 Dec; 146(6):1208-14. View in PubMed
  28. Lin CI, Whang EE, Donner DB, Jiang X, Price BD, Carothers AM, Delaine T, Leffler H, Nilsson UJ, Nose V, Moore FD, Ruan DT. Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Mol Cancer Res. 2009 Oct; 7(10):1655-62. View in PubMed
  29. Satpathy M, Shao M, Emerson R, Donner DB, Matei D. Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity. J Biol Chem. 2009 Jun 05; 284(23):15390-9. View in PubMed
  30. Y. Wang, M. Zuraek, D. Donner, E. Bergsland, R. Warren, E.K. Nakakura. QS138. The FEV Transcription Factor is Abberantly Expressed in Neuroendocrine Tumors of the Small Intestine. Journal of Surgical Research. 2009 Feb 1; 151(2):288. View in PubMed
  31. Testori A, De Salvo GL, Montesco MC, Trifirò G, Mocellin S, Landi G, Macripò G, Carcoforo P, Ricotti G, Giudice G, Picciotto F, Donner D, Di Filippo F, Soteldo J, Casara D, Schiavon M, Vecchiato A, Pasquali S, Baldini F, Mazzarol G, Rossi CR, Italian Melanoma Intergroup . Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI). Ann Surg Oncol. 2009 Jul; 16(7):2018-27. View in PubMed
  32. Pincheira R, Baerwald M, Dunbar JD, Donner DB. Sall2 is a novel p75NTR-interacting protein that links NGF signalling to cell cycle progression and neurite outgrowth. EMBO J. 2009 Feb 04; 28(3):261-73. View in PubMed
  33. Lin CI, Whang EE, Abramson MA, Donner DB, Bertagnolli MM, Moore FD, Ruan DT. Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem Biophys Res Commun. 2009 Feb 06; 379(2):626-31. View in PubMed
  34. Ruan DT, Warren RS, Moalem J, Chung KW, Griffin AC, Shen W, Duh QY, Nakakura E, Donner DB, Khanafshar E, Weng J, Clark OH, Kebebew E. Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers. Surgery. 2008 Dec; 144(6):908-13; discussion 913-4. View in PubMed
  35. Wang YC, Gallego-Arteche E, Iezza G, Yuan X, Matli MR, Choo SP, Zuraek MB, Gogia R, Lynn FC, German MS, Bergsland EK, Donner DB, Warren RS, Nakakura EK. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors. Endocr Relat Cancer. 2009 Mar; 16(1):267-79. View in PubMed
  36. Pincheira R, Donner DB. The Sall2 transcription factor is a novel p75NTR binding protein that promotes the development and function of neurons. Ann N Y Acad Sci. 2008 Nov; 1144:53-5. View in PubMed
  37. Pincheira R, Castro AF, Ozes ON, Idumalla PS, Donner DB. Type 1 TNF receptor forms a complex with and uses Jak2 and c-Src to selectively engage signaling pathways that regulate transcription factor activity. J Immunol. 2008 Jul 15; 181(2):1288-98. View in PubMed
  38. LaRusch GA, Jackson MW, Dunbar JD, Warren RS, Donner DB, Mayo LD. Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. Cancer Res. 2007 Jan 15; 67(2):450-4. View in PubMed
  39. Matei D, Satpathy M, Cao L, Lai YC, Nakshatri H, Donner DB. The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells. J Biol Chem. 2007 Jan 05; 282(1):445-53. View in PubMed
  40. Jackson MW, Patt LE, LaRusch GA, Donner DB, Stark GR, Mayo LD. Hdm2 nuclear export, regulated by insulin-like growth factor-I/MAPK/p90Rsk signaling, mediates the transformation of human cells. J Biol Chem. 2006 Jun 16; 281(24):16814-20. View in PubMed
  41. Gustin JA, Korgaonkar CK, Pincheira R, Li Q, Donner DB. Akt regulates basal and induced processing of NF-kappaB2 (p100) to p52. J Biol Chem. 2006 Jun 16; 281(24):16473-81. View in PubMed
  42. Schmidt NW, Mayo LD, Donner DB, Kaplan MH. p53 regulates Btk-dependent B cell proliferation but not differentiation. J Leukoc Biol. 2006 Apr; 79(4):852-9. View in PubMed
  43. D. Matei, Y.-C. Lai, J. Rao, R. Emerson, D. Donner. PDGFR is activated through an autocrine mechanism in ovarian cancer. Journal of Clinical Oncology. 2005 Jun 1; 23(16_suppl):5073-5073. View in PubMed
  44. Mayo LD, Seo YR, Jackson MW, Smith ML, Rivera Guzman J, Korgaonkar CK, Donner DB. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem. 2005 Jul 15; 280(28):25953-9. View in PubMed
  45. Osman Nidai Ozes, Hakan Akca, Jason A. Gustin, Lindsey D. Mayo, Roxana Pincheira, Chandrashekhar K. Korgaonkar, David B. Donner. Tumor Necrosis Factor-a/Receptor Signaling Through the Akt Kinase. Cell Signaling in Vascular Inflammation. 2005 Jan 1; 13-22. View in PubMed
  46. Toussaint-Smith E, Donner DB, Roman A. Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene. 2004 Apr 15; 23(17):2988-95. View in PubMed
  47. Gustin JA, Pincheira R, Mayo LD, Ozes ON, Kessler KM, Baerwald MR, Korgaonkar CK, Donner DB. Tumor necrosis factor activates CRE-binding protein through a p38 MAPK/MSK1 signaling pathway in endothelial cells. . 2004 Mar; 286(3):C547-55. View in PubMed
  48. Gustin JA, Ozes ON, Akca H, Pincheira R, Mayo LD, Li Q, Guzman JR, Korgaonkar CK, Donner DB. Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation. J Biol Chem. 2004 Jan 16; 279(3):1615-20. View in PubMed
  49. Su JD, Mayo LD, Donner DB, Durden DL. PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res. 2003 Jul 01; 63(13):3585-92. View in PubMed
  50. Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci. 2002 Sep; 27(9):462-7. View in PubMed
  51. Wang D, Lehman RE, Donner DB, Matli MR, Warren RS, Welton ML. Expression and endocytosis of VEGF and its receptors in human colonic vascular endothelial cells. Am J Physiol Gastrointest Liver Physiol. 2002 Jun; 282(6):G1088-96. View in PubMed
  52. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem. 2002 Feb 15; 277(7):5484-9. View in PubMed
  53. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A. 2001 Sep 25; 98(20):11598-603. View in PubMed
  54. Gustin JA, Maehama T, Dixon JE, Donner DB. The PTEN tumor suppressor protein inhibits tumor necrosis factor-induced nuclear factor kappa B activity. J Biol Chem. 2001 Jul 20; 276(29):27740-4. View in PubMed
  55. Mayo LD, Kessler KM, Pincheira R, Warren RS, Donner DB. Vascular endothelial cell growth factor activates CRE-binding protein by signaling through the KDR receptor tyrosine kinase. J Biol Chem. 2001 Jul 06; 276(27):25184-9. View in PubMed
  56. Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE, Donner DB. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci U S A. 2001 Apr 10; 98(8):4640-5. View in PubMed
  57. Yang CH, Murti A, Pfeffer SR, Kim JG, Donner DB, Pfeffer LM. Interferon alpha /beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt. J Biol Chem. 2001 Apr 27; 276(17):13756-61. View in PubMed
  58. Osman Nidai Ozes, Lindsey D. Mayo, Jason A. Gustin, Susan R. Pfeffer, Lawrence M. Pfeffer, David B. Donner. reply: Kinase regulation in inflammatory response. Nature. 2000 Jul 1; 406(6794):368-368. View in PubMed
  59. Wang D, Donner DB, Warren RS. Homeostatic modulation of cell surface KDR and Flt1 expression and expression of the vascular endothelial cell growth factor (VEGF) receptor mRNAs by VEGF. J Biol Chem. 2000 May 26; 275(21):15905-11. View in PubMed
  60. Guo DQ, Wu LW, Dunbar JD, Ozes ON, Mayo LD, Kessler KM, Gustin JA, Baerwald MR, Jaffe EA, Warren RS, Donner DB. Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem. 2000 Apr 14; 275(15):11216-21. View in PubMed
  61. Wu LW, Mayo LD, Dunbar JD, Kessler KM, Ozes ON, Warren RS, Donner DB. VRAP is an adaptor protein that binds KDR, a receptor for vascular endothelial cell growth factor. J Biol Chem. 2000 Mar 03; 275(9):6059-62. View in PubMed
  62. Wu LW, Mayo LD, Dunbar JD, Kessler KM, Baerwald MR, Jaffe EA, Wang D, Warren RS, Donner DB. Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem. 2000 Feb 18; 275(7):5096-103. View in PubMed
  63. Pazdernik NJ, Donner DB, Goebl MG, Harrington MA. Mouse receptor interacting protein 3 does not contain a caspase-recruiting or a death domain but induces apoptosis and activates NF-kappaB. Mol Cell Biol. 1999 Oct; 19(10):6500-8. View in PubMed
  64. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999 Sep 02; 401(6748):82-5. View in PubMed
  65. Vig E, Green M, Liu Y, Donner DB, Mukaida N, Goebl MG, Harrington MA. Modulation of tumor necrosis factor and interleukin-1-dependent NF-kappaB activity by mPLK/IRAK. J Biol Chem. 1999 May 07; 274(19):13077-84. View in PubMed
  66. Wu LW, Reid S, Ritchie A, Broxmeyer HE, Donner DB. The proteasome regulates caspase-dependent and caspase-independent protease cascades during apoptosis of MO7e hematopoietic progenitor cells. Blood Cells Mol Dis. 1999 Feb; 25(1):20-9. View in PubMed
  67. Ankoma-Sey V, Matli M, Chang KB, Lalazar A, Donner DB, Wong L, Warren RS, Friedman SL. Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing. Oncogene. 1998 Jul 09; 17(1):115-21. View in PubMed
  68. Guo D, Dunbar JD, Yang CH, Pfeffer LM, Donner DB. Induction of Jak/STAT signaling by activation of the type 1 TNF receptor. J Immunol. 1998 Mar 15; 160(6):2742-50. View in PubMed
  69. Dunbar JD, Song HY, Guo D, Wu LW, Donner DB. Two-hybrid cloning of a gene encoding TNF receptor-associated protein 2, a protein that interacts with the intracellular domain of the type 1 TNF receptor: identity with subunit 2 of the 26S protease. J Immunol. 1997 May 01; 158(9):4252-9. View in PubMed
  70. Warren RS, Yuan H, Matli MR, Ferrara N, Donner DB. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem. 1996 Nov 15; 271(46):29483-8. View in PubMed
  71. Marino MW, Dunbar JD, Wu LW, Ngaiza JR, Han HM, Guo D, Matsushita M, Nairn AC, Zhang Y, Kolesnick R, Jaffe EA, Donner DB. Inhibition of tumor necrosis factor signal transduction in endothelial cells by dimethylaminopurine. J Biol Chem. 1996 Nov 08; 271(45):28624-9. View in PubMed
  72. Broxmeyer HE, Cooper S, Li ZH, Lu L, Sarris A, Wang MH, Chang MS, Donner DB, Leonard EJ. Macrophage-stimulating protein, a ligand for the RON receptor protein tyrosine kinase, suppresses myeloid progenitor cell proliferation and synergizes with vascular endothelial cell growth factor and members of the chemokine family. Ann Hematol. 1996 Jul; 73(1):1-9. View in PubMed
  73. Guo D, Donner DB. Tumor necrosis factor promotes phosphorylation and binding of insulin receptor substrate 1 to phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. J Biol Chem. 1996 Jan 12; 271(2):615-8. View in PubMed
  74. Broxmeyer HE, Cooper S, Li ZH, Lu L, Song HY, Kwon BS, Warren RE, Donner DB. Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor. Int J Hematol. 1995 Dec; 62(4):203-15. View in PubMed
  75. Song HY, Donner DB. Association of a RING finger protein with the cytoplasmic domain of the human type-2 tumour necrosis factor receptor. Biochem J. 1995 Aug 01; 309 ( Pt 3):825-9. View in PubMed
  76. Guo D, Jia Q, Song HY, Warren RS, Donner DB. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem. 1995 Mar 24; 270(12):6729-33. View in PubMed
  77. Song HY, Dunbar JD, Zhang YX, Guo D, Donner DB. Identification of a protein with homology to hsp90 that binds the type 1 tumor necrosis factor receptor. J Biol Chem. 1995 Feb 24; 270(8):3574-81. View in PubMed
  78. Song HY, Dunbar JD, Donner DB. Aggregation of the intracellular domain of the type 1 tumor necrosis factor receptor defined by the two-hybrid system. J Biol Chem. 1994 Sep 09; 269(36):22492-5. View in PubMed
  79. Blumberg D, Tsuburaya A, Burt M, Donner DB, Brennan MF. Acute metabolic effects of human recombinant tumor necrosis factor beta in the rat. Ann Surg Oncol. 1994 Sep; 1(5):373-7. View in PubMed
  80. Ahn J, Rosen OM, Donner DB. Human insulin receptor mutated at threonine 1336 functions normally in Chinese hamster ovary cells. J Biol Chem. 1993 Aug 05; 268(22):16839-44. View in PubMed
  81. Schwalb DM, Han HM, Marino M, Warren R, Porter A, Goh C, Fair WR, Donner DB. Identification of a new receptor subtype for tumor necrosis factor-alpha. J Biol Chem. 1993 May 15; 268(14):9949-52. View in PubMed
  82. Ahn J, Donner DB, Rosen OM. Interaction of the human insulin receptor tyrosine kinase from the baculovirus expression system with protein kinase C in a cell-free system. J Biol Chem. 1993 Apr 05; 268(10):7571-6. View in PubMed
  83. Manchester KM, Heston WD, Donner DB. Tumour necrosis factor-induced cytotoxicity is accompanied by intracellular mitogenic signals in ME-180 human cervical carcinoma cells. Biochem J. 1993 Feb 15; 290 ( Pt 1):185-90. View in PubMed
  84. Kinouchi K, Brown G, Pasternak G, Donner DB. Identification and characterization of receptors for tumor necrosis factor-alpha in the brain. Biochem Biophys Res Commun. 1991 Dec 31; 181(3):1532-8. View in PubMed
  85. Marino MW, Feld LJ, Jaffe EA, Pfeffer LM, Han HM, Donner DB. Phosphorylation of the proto-oncogene product eukaryotic initiation factor 4E is a common cellular response to tumor necrosis factor. J Biol Chem. 1991 Feb 15; 266(5):2685-8. View in PubMed
  86. Han HM, Kolhatkar AA, Marino MW, Manchester KM, Donner DB. Identification, characterization, and homologous up-regulation of latent (cryptic) receptors for tumor necrosis factor-alpha in rat liver plasma membranes. J Biol Chem. 1990 Oct 25; 265(30):18590-4. View in PubMed
  87. Pfeffer LM, Donner DB. The down-regulation of alpha-interferon receptors in human lymphoblastoid cells: relation to cellular responsiveness to the antiproliferative action of alpha-interferon. Cancer Res. 1990 May 01; 50(9):2654-7. View in PubMed
  88. Bodnar RJ, Pasternak GW, Mann PE, Paul D, Warren R, Donner DB. Mediation of anorexia by human recombinant tumor necrosis factor through a peripheral action in the rat. Cancer Res. 1989 Nov 15; 49(22):6280-4. View in PubMed
  89. Marino MW, Pfeffer LM, Guidon PT, Donner DB. Tumor necrosis factor induces phosphorylation of a 28-kDa mRNA cap-binding protein in human cervical carcinoma cells. Proc Natl Acad Sci U S A. 1989 Nov; 86(21):8417-21. View in PubMed
  90. Lipson KE, Kolhatkar AA, Donner DB. Insulin stimulates proteolysis of the alpha-subunit, but not the beta-subunit, of its receptor at the cell surface in rat liver. Biochem J. 1989 Jul 15; 261(2):333-40. View in PubMed
  91. Lipson KE, Kolhatkar AA, Donner DB. Alkylation, reduction, solubilization and enrichment of binding activity do not impair the ability of insulin receptors to convert from a rapid- into a slow-dissociating state. Biochem J. 1989 May 01; 259(3):871-8. View in PubMed
  92. Meyers MB, Shen WP, Spengler BA, Ciccarone V, O'Brien JP, Donner DB, Furth ME, Biedler JL. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. J Cell Biochem. 1988 Oct; 38(2):87-97. View in PubMed
  93. Lipson KE, Kolhatkar AA, Donner DB. Cell surface proteolysis and down-regulation of the hepatic insulin receptor. Evidence for selective sorting of intact and degraded receptors after internalization. J Biol Chem. 1988 Jul 25; 263(21):10495-501. View in PubMed
  94. Lipson KE, Kolhatkar AA, Maki RG, Donner DB. Divalent cations regulate glucagon binding. Evidence for actions on receptor-Ns complexes and on receptors uncoupled from Ns. Biochemistry. 1988 Feb 23; 27(4):1111-6. View in PubMed
  95. Warren RS, Donner DB, Starnes HF, Brennan MF. Modulation of endogenous hormone action by recombinant human tumor necrosis factor. Proc Natl Acad Sci U S A. 1987 Dec; 84(23):8619-22. View in PubMed
  96. Yamada K, Lipson KE, Donner DB. Structure and proteolysis of the growth hormone receptor on rat hepatocytes. Biochemistry. 1987 Jul 14; 26(14):4438-43. View in PubMed
  97. Lawrence M. Pfeffer, David B. Donner, Tsutomu Arakawa, Nowell Stebbing, Igor Tamm. Early Events in the Interaction of IFN-a with IFN-Sensitive and IFN-Resistant Daudi Cells. The Biology of the Interferon System 1986. 1987 Jan 1; 99-105. View in PubMed
  98. David B. Donner, Kazuyo Yamada, Kenneth E. Lipson, Andrea Dorato. Structural Studies of the Growth Hormone Receptor by Affinity Labeling. Human Growth Hormone. 1986 Jan 1; 463-473. View in PubMed
  99. Yamada K, Donner DB. Evidence that non-covalent forces, thiol and disulphide groups affect the structure and binding properties of the prolactin receptor on hepatocytes from pregnant rats. Biochem J. 1985 Jun 01; 228(2):383-90. View in PubMed
  100. Yamada K, Donner DB. Structures of the somatotropin receptor and prolactin receptor on rat hepatocytes characterized by affinity labelling. Biochem J. 1984 Jun 01; 220(2):361-9. View in PubMed
  101. Corin RE, Donner DB. Insulin binding to liver plasma membranes from rats rendered diabetic by alloxan. A kinetic demonstration of two classes of binding sites in equilibrium with each other. Biochem J. 1982 Jan 15; 202(1):259-62. View in PubMed
  102. Robert E. Corin, F.C. Bancroft, David B. Donner. BINDING, INTERNALIZATION, AND DEGRADATION OF 125I-INSULIN BY CULTURED RAT PITUITARY TUMOR CELLS. Cellular Responses to Molecular Modulators. 1981 Jan 1; 504. View in PubMed
  103. Donner DB, Casadei J, Hartstein L, Martin D, Sonenberg M. Characterization of the slowly dissociable human growth hormone binding component of isolated rat hepatocytes. Biochemistry. 1980 Jul 08; 19(14):3293-300. View in PubMed
  104. Donner DB. Interconversion between different states of affinity of the human growth hormone receptor on rat hepatocytes: effects of fractional site occupancy on receptor availability. Biochemistry. 1980 Jul 08; 19(14):3300-6. View in PubMed
  105. Fu JL, Donner DB, Hess GP. Half-of-the-sites reactivity of the membrane-bound Electrophorus electricus acetylcholine receptor. Biochem Biophys Res Commun. 1974 Oct 08; 60(3):1072-80. View in PubMed